Drug screening to identify suppressors of GFAP expression

Human Molecular Genetics

Volumn 19, Issue 16, 2010, Pages 3169-3178

  Cho, Woosung ^a   Brenner, Michael ^c   Peters, Noel ^b   Messing, Albee ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; AMLODIPINE; CHLORPROTHIXENE; CHRYSOPHANIC ACID; CLOMIPRAMINE; DIAZIQUONE; EMBELIN; EPIGALLOCATECHIN 3,5 DIGALLATE; GLIAL FIBRILLARY ACIDIC PROTEIN; MUNDOSERONE; PROTEIN SYNTHESIS INHIBITOR; TAMOXIFEN CITRATE; UNCLASSIFIED DRUG;

ALEXANDER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN LEVEL; CELL LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG SCREENING; FEMALE; GLIOSIS; IC 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; REGULATORY MECHANISM; SINGLE DRUG DOSE;

AMITRIPTYLINE; ANIMALS; ANIMALS, NEWBORN; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ASTROCYTES; CELLS, CULTURED; CLOMIPRAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; LUCIFERASES; MICE; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE; PROMOTER REGIONS, GENETIC; TIME FACTORS;

MUS; VERTEBRATA;

EID: 77955032303     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddq227     Document Type: Article

References (52)

1. Eng, L.F., Ghirnikar, R.S. and Lee, Y.L. (2000) Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000). Neurochem. Res., 25, 1439-1451.
2. Eng, L.F. and Ghirnikar, R.S. (1994) GFAP and astrogliosis. Brain Pathol., 4, 229-237.
3. Brenner, M., Johnson, A.B., Boespflug-Tanguy, O., Rodriguez, D., Goldman, J.E. and Messing, A. (2001) Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease. Nat. Genet., 27, 117-120.
4. Li, R., Johnson, A.B., Salomons, G., Goldman, J.E., Naidu, S., Quinlan, R., Cree, B., Ruyle, S.Z., Banwell, B., D'Hooghe, M. et al. (2005) GFAP mutations in infantile, juvenile, and adult forms of Alexander disease. Ann. Neurol., 57, 310-326.
5. Quinlan, R.A., Brenner, M., Goldman, J. and Messing, A. (2007) GFAP and its role in Alexander disease. Exp. Cell Res., 313, 2077-2087.
6. Hagemann, T.L., Connor, J.X. and Messing, A. (2006) Alexander disease-associated glial fibrillary acidic protein mutations in mice induce Rosenthal fiber formation and a white matter stress response. J. Neurosci., 26, 11162-11173.
7. Heemskerk, J., Tobin, A.J. and Bain, L.J. (2002) Teaching old drugs new tricks. Trends Neurosci., 25, 494-496.
8. Rothstein, J.D., Patel, S., Regan, M.R., Haenggeli, C., Huang, Y.H., Bergles, D.E., Jin, L., Hoberg, M.D., Vidensky, S., Chung, D.S. et al. (2005) b-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature, 433, 73-77.
9. Piccioni, F., Roman, B.R., Fischbeck, K.H. and Taylor, J.P. (2004) A screen for drugs that protect against the cytotoxicity of polyglutamine-expanded androgen receptor. Hum. Mol. Genet., 13, 437-446.
10. Brenner, M. (1994) Structure and transcriptional regulation of the GFAP gene. Brain Pathol., 4, 245-257. Human Molecular Genetics, 2010, Vol. 19, No. 16 3177
11. Laping, N.J., Teter, B., Nichols, N.R., Rozovsky, I. and Finch, C.E. (1994) Glial fibrillary acidic protein: regulation by hormones, cytokines, and growth factors. Brain Pathol., 4, 259-275.
12. Mucke, L., Oldstone, M.B.A., Morris, J.C. and Nerenberg, M.I. (1991) Rapid activation of astrocyte-specific expression of GFAP-lacZ transgene by focal injury. New Biol., 3, 465-474.
13. Brenner, M., Kisseberth, W.C., Su, Y., Besnard, F. and Messing, A. (1994) GFAP promoter directs astrocyte-specific expression in transgenic mice. J. Neurosci., 14, 1030-1037.
14. Cho, W., Hagemann, T.L., Johnson, D.A., Johnson, J.A. and Messing, A. (2009) Dual transgenic reporter mice as a tool for monitoring expression of GFAP. J. Neurochem., 110, 343-351.
15. Zhang, J.H., Chung, T.D. and Oldenburg, K.R. (1999) A simple statistical parameter for use in evaluation and validation of high-throughput screening assays. J. Biomol. Screen., 4, 67-73.
16. DeArmond, S.J., Lee, Y.-L., Kretzschmar, H.A. and Eng, L.F. (1986) Turnover of glial filaments in mouse spinal cord. J. Neurochem., 47, 1749-1753.
17. Hagemann, T.L., Gaeta, S.A., Smith, M.A., Johnson, D.A., Johnson, J.A. and Messing, A. (2005) Gene expression analysis in mice with elevated glial fibrillary acidic protein and Rosenthal fibers reveals a stress response followed by glial activation and neuronal dysfunction. Hum. Mol. Genet., 14, 2443-2458.
18. Tang, G., Xu, Z. and Goldman, J.E. (2006) Synergistic effects of the SAPK/JNK and the proteasome pathway on glial fibrillary acidic protein (GFAP) accumulation in Alexander disease. J. Biol. Chem., 281, 38634-38643.
19. Tian, R.J., Gregor, M., Wiche, G. and Goldman, J.E. (2006) Plectin regulates the organization of glial fibrillary acidic protein in Alexander disease. Am. J. Pathol., 168, 888-897.
20. Cho, W. and Messing, A. (2009) Properties of astrocytes cultured from GFAP over-expressing and GFAP mutant mice. Exp. Cell Res., 315, 1260-1272.
21. Carlsson, A., Corrodi, H., Fuxe, K. and Hökfelt, T. (1969) Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl-alpha-ethyl-meta-tyramine. Eur. J. Pharmacol., 357, 366.
22. Carlsson, A. (1970) Structural specificity for inhibition of [14C]-5-hydroxytryptamine uptake by cerebral slices. J. Pharm. Pharmacol., 22, 729-732.
23. Ross, S.B., Renyi, A.L. and Ogren, S.O. (1972) Inhibition of the uptake of noradrenaline and 5-hydroxytryptamine by chlorphentermine and chlorimipramine. Eur. J. Pharmacol., 17, 107-112.
24. Baldessarini, R.J. (2006) In Brunton, L.R., Lazo, J.S. and Parker, K.L. (eds), The Pharmacological Basis of Therapeutics. McGraw-Hill, New York, pp. 429-459.
25. Wille, S.M., Cooreman, S.G., Neels, H.M. and Lambert, W.E. (2008) Relevant issues in the monitoring and the toxicology of antidepressants. Crit. Rev. Clin. Lab. Sci., 45, 25-89.
26. Stern, R.S., Marks, I.M., Mawson, D. and Luscombe, D.K. (1980) Clomipramine and exposure for compulsive rituals: II. Plasma levels, side effects and outcome. Br. J. Psychiatry, 136, 161-166.
27. Insel, T.R., Murphy, D.L., Cohen, R.M., Alterman, I., Kilts, C. and Linnoila, M. (1983) Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline. Arch. Gen. Psychiatry, 40, 605-612.
28. Glazener, C.M., Evans, J.H. and Peto, R.E. (2003) Tricyclic and related drugs for nocturnal enuresis in children. Cochrane Database Syst. Rev., 3, CD002117.
29. Shapiro, W.R. (1975) Treatment of cataplexy with clomipramine. Arch. Neurol., 32, 653-656.
30. Haensel, S.M., Rowland, D.L. and Kallan, K.T. (1996) Clomipramine and sexual function in men with premature ejaculation and controls. J. Urol., 156, 1310-1315.
31. Faravelli, C., Ballerini, A., Ambonetti, A., Broadhurst, A.D. and Das, M. (1984) Plasma levels and clinical response during treatment with clomipramine. J. Affect. Disord., 6, 95-107.
32. Caillard, V., Rouillon, F., Viel, J.F. and Markabi, S. (1999) Comparative effects of low and high doses of clomipramine and placebo in panic disorder: a double-blind controlled study. French University Antidepressant Group. Acta Psychiatr. Scand., 99, 51-58.
33. Sugimoto, Y., Inoue, K. and Yamada, J. (2003) The tricyclic antidepressant clomipramine increases plasma glucose levels of mice. J. Pharmacol. Sci., 93, 74-79.
34. Walz, W. (1995) In Kettenmann, H. and Ransom, B.R. (eds), Neuroglia. Oxford University Press, New York, pp. 346-353.
35. Balant-Gorgia, A.E., Gex-Fabry, M. and Balant, L.P. (1991) Clinical pharmacokinetics of clomipramine. Clin. Pharmacokinet., 20, 447-462.
36. Takizawa, T., Nakashima, K., Namihira, M., Ochiai, W., Uemura, A., Yanagisawa, M., Fujita, N., Nakao, M. and Taga, T. (2001) DNA methylation is a critical cell-intrinsic determinant of astrocyte differentiation in the fetal brain. Dev. Cell, 1, 749-758.
37. Herrmann, J.E., Imura, T., Song, B.B., Qi, J.W., Ao, Y., Nguyen, T.K., Korsak, R.A., Takeda, K., Akira, S. and Sofroniew, M.V. (2008) STAT3 is a critical regulator of astrogliosis and scar formation after spinal cord injury. J. Neurosci., 28, 7231-7243.
38. Krohn, K., Rozovsky, I., Wals, P., Teter, B., Anderson, C.P. and Finch, C.E. (1999) Glial fibrillary acidic protein transcription responses to transforming growth factor-β1 and interleukin-1β are mediated by a nuclear factor-1-like site in the near-upstream promoter. J. Neurochem., 72, 1353-1361.
39. Masood, K., Besnard, F., Su, Y. and Brenner, M. (1993) Analysis of a segment of the human glial fibrillary acidic protein gene that directs astrocyte-specific transcription. J. Neurochem., 61, 160-166.
40. Besnard, F., Brenner, M., Nakatani, Y., Chao, R., Purohit, H.J. and Freese, E. (1991) Multiple interacting sites regulate astrocyte-specific transcription of the human gene for glial fibrillary acidic protein. J. Biol. Chem., 266, 18877-18883.
41. Lee, Y., Su, M., Messing, A. and Brenner, M. (2006) Astrocyte heterogeneity revealed by expression of a GFAP-LacZ transgene. Glia, 53, 677-687.
42. Hwang, J., Zheng, L.T., Ock, J., Lee, M.G., Kim, S.H., Lee, H.W., Lee, W.H., Park, H.C. and Suk, K. (2008) Inhibition of glial inflammatory activation and neurotoxicity by tricyclic antidepressants. Neuropharmacology, 55, 826-834.
43. Millecamps, S., Gowing, G., Corti, O., Mallet, J. and Julien, J.P. (2007) Conditional NF-L transgene expression in mice for in vivo analysis of turnover and transport rate of neurofilaments. J. Neurosci., 27, 4947-4956.
44. Yuan, A.D., Sasaki, T., Rao, M.V., Kumar, A., Kanumuri, V., Dunlop, D.S., Liem, R.K. and Nixon, R.A. (2009) Neurofilaments form a highly stable stationary cytoskeleton after reaching a critical level in axons. J. Neurosci., 29, 11316-11329.
45. Chiu, F.C. and Goldman, J.E. (1984) Synthesis and turnover of cytoskeletal proteins in cultured astrocytes. J. Neurochem., 42, 166-174.
46. Morrison, R.S., de Vellis, J., Lee, Y.L., Bradshaw, R.A. and Eng, L.F. (1985) Hormones and growth factors induce the synthesis of glial fibrillary acidic protein in rat brain astrocytes. J. Neurosci. Res., 14, 167-176.
47. Eddleston, M. and Mucke, L. (1993) Molecular profile of reactive astrocytes-Implications for their role in neurologic disease. Neuroscience, 54, 15-36.
48. Pekny, M. and Nilsson, M. (2005) Astrocyte activation and reactive gliosis. Glia, 50, 427-434.
49. Sofroniew, M.V. (2009) Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci., 32, 638-647.
50. Schilsky, R.L., Kelley, J.A., Ihde, D.C., Howser, D.M., Cordes, R.S. and Young, R.C. (1982) Phase I trial and pharmacokinetics of aziridinylbenzoquinone (NSC 182986) in humans. Cancer Res., 42, 1582-1586.
51. McCall, M.A., Gregg, R.G., Behringer, R.R., Brenner, M., Delaney, C.L., Galbreath, E.J., Zhang, C.L., Pearce, R.A., Chiu, S.Y. and Messing, A. (1996) Targeted deletion in astrocyte intermediate filament (Gfap) alters neuronal physiology. Proc. Natl Acad. Sci. USA, 93, 6361-6366.
52. Saldhana, A.J. (2004) Java Treeview-extensible visualization of microarray data. Bioinformatics, 20, 3246-3248.